Heart failure & cardiomyopathies
Rationale and Design of the Randomized ‘Early Ventricular Assist Device’—Trial (VAD-DZHK3)
Study context
- Population
- Patients with end-stage HF listed for cardiac transplantation
- Planned comparison
- An early strategy of elective left ventricular assist devices (LVAD) implantation improves outcomes compared with a conventional approach involving optimal medical therapy and delayed device implantation only after clinical deterioration
- Primary endpoint
- survival free from high urgent cardiac transplantation, disabling stroke and HF hospitalizations (including emergency room HF visits >6 h)
Methodological detailsevent-driven study, parallel observational registry for patients who decline randomization
- Event-driven study
- Parallel observational registry for patients who decline randomization
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Study conduct
- Study completed once 120 events of the primary composite endpoint have been observed and all patients have at least 1 year of follow-up unless they died earlier
- 120
- Event-driven study
Original publication
Rationale and Design of the Randomized ‘Early Ventricular Assist Device’—Trial (VAD-DZHK3). ESC Heart Fail. Published 20 July 2025. doi:10.
Summarised from the published abstract; every number is checked against it